A number of other research firms also recently issued reports on DCPH. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $40.00 price objective on the stock in a report on Friday, October 4th. HC Wainwright assumed coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, October 3rd. They issued a buy rating and a $60.00 price objective on the stock. SunTrust Banks raised their price objective on shares of Deciphera Pharmaceuticals to $60.00 and gave the stock a buy rating in a report on Wednesday, August 14th. Cantor Fitzgerald raised their price objective on shares of Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the stock an overweight rating in a report on Wednesday, August 14th. Finally, Deutsche Bank assumed coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, July 18th. They issued a buy rating and a $42.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $50.27.
Shares of DCPH stock opened at $34.86 on Friday. The company has a 50 day moving average price of $34.89 and a 200-day moving average price of $27.34. Deciphera Pharmaceuticals has a 52 week low of $18.55 and a 52 week high of $42.99. The firm has a market capitalization of $1.73 billion, a PE ratio of -12.36 and a beta of 1.89. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.01.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to the consensus estimate of $20.00 million. Analysts anticipate that Deciphera Pharmaceuticals will post -4.05 earnings per share for the current year.
In other Deciphera Pharmaceuticals news, major shareholder New Leaf Venture Management Ii sold 350,000 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $36.42, for a total transaction of $12,747,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Thomas Patrick Kelly sold 11,250 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $41.27, for a total transaction of $464,287.50. The disclosure for this sale can be found here. In the last three months, insiders sold 576,107 shares of company stock worth $21,748,018. 7.02% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in Deciphera Pharmaceuticals by 25.6% during the second quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock valued at $34,543,000 after purchasing an additional 311,870 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Deciphera Pharmaceuticals by 2.6% during the second quarter. Vanguard Group Inc. now owns 792,654 shares of the company’s stock valued at $17,874,000 after purchasing an additional 20,252 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Deciphera Pharmaceuticals by 2.1% during the second quarter. Janus Henderson Group PLC now owns 675,707 shares of the company’s stock valued at $15,237,000 after purchasing an additional 14,028 shares in the last quarter. Eversept Partners LP lifted its holdings in Deciphera Pharmaceuticals by 21.9% during the second quarter. Eversept Partners LP now owns 305,233 shares of the company’s stock valued at $6,883,000 after purchasing an additional 54,801 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Deciphera Pharmaceuticals during the second quarter valued at approximately $4,606,000. 45.69% of the stock is currently owned by institutional investors and hedge funds.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Recommended Story: What is the balance sheet?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.